VANCOUVER, British Columbia, June 22, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has completed the clinical trials, a pharmacokinetics (PK) study in Europe under EMEA guideline and the final report has been obtained.
